Logo image of ATHA

ATHIRA PHARMA INC (ATHA) Stock Fundamental Analysis

NASDAQ:ATHA - Nasdaq - US04746L1044 - Common Stock - Currency: USD

0.4341  -0.01 (-3.21%)

Fundamental Rating

2

Overall ATHA gets a fundamental rating of 2 out of 10. We evaluated ATHA against 193 industry peers in the Pharmaceuticals industry. The financial health of ATHA is average, but there are quite some concerns on its profitability. ATHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATHA had negative earnings in the past year.
ATHA had a negative operating cash flow in the past year.
ATHA had negative earnings in each of the past 5 years.
In the past 5 years ATHA always reported negative operating cash flow.
ATHA Yearly Net Income VS EBIT VS OCF VS FCFATHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -126.64%, ATHA is doing worse than 83.15% of the companies in the same industry.
With a Return On Equity value of -189.68%, ATHA is not doing good in the industry: 71.20% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -126.64%
ROE -189.68%
ROIC N/A
ROA(3y)-42.33%
ROA(5y)-73.74%
ROE(3y)-49.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHA Yearly ROA, ROE, ROICATHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

ATHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHA Yearly Profit, Operating, Gross MarginsATHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

ATHA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATHA has been increased compared to 5 years ago.
There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHA Yearly Shares OutstandingATHA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
ATHA Yearly Total Debt VS Total AssetsATHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ATHA has an Altman-Z score of -9.68. This is a bad value and indicates that ATHA is not financially healthy and even has some risk of bankruptcy.
ATHA's Altman-Z score of -9.68 is on the low side compared to the rest of the industry. ATHA is outperformed by 75.00% of its industry peers.
ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.68
ROIC/WACCN/A
WACCN/A
ATHA Yearly LT Debt VS Equity VS FCFATHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.95 indicates that ATHA has no problem at all paying its short term obligations.
ATHA has a Current ratio (2.95) which is comparable to the rest of the industry.
A Quick Ratio of 2.95 indicates that ATHA has no problem at all paying its short term obligations.
ATHA has a Quick ratio of 2.95. This is comparable to the rest of the industry: ATHA outperforms 52.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
ATHA Yearly Current Assets VS Current LiabilitesATHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.06% over the past year.
EPS 1Y (TTM)2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.29%
EPS Next 2Y16.64%
EPS Next 3Y20.11%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATHA Yearly Revenue VS EstimatesATHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10K 20K 30K 40K 50K
ATHA Yearly EPS VS EstimatesATHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATHA. In the last year negative earnings were reported.
Also next year ATHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHA Price Earnings VS Forward Price EarningsATHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHA Per share dataATHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ATHA's earnings are expected to grow with 20.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.64%
EPS Next 3Y20.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATHIRA PHARMA INC

NASDAQ:ATHA (2/21/2025, 8:02:06 PM)

0.4341

-0.01 (-3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners36.76%
Inst Owner Change-88.11%
Ins Owners2.93%
Ins Owner Change9.72%
Market Cap16.79M
Analysts48.89
Price Target0.56 (29%)
Short Float %2.99%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.37%
Min EPS beat(2)-4.12%
Max EPS beat(2)6.86%
EPS beat(4)3
Avg EPS beat(4)11.16%
Min EPS beat(4)-4.12%
Max EPS beat(4)27.47%
EPS beat(8)5
Avg EPS beat(8)6.25%
EPS beat(12)9
Avg EPS beat(12)7.21%
EPS beat(16)12
Avg EPS beat(16)9.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-0.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-2.85
EYN/A
EPS(NY)-1.98
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -126.64%
ROE -189.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.33%
ROA(5y)-73.74%
ROE(3y)-49.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z -9.68
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)164.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y16.29%
EPS Next 2Y16.64%
EPS Next 3Y20.11%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.31%
EBIT Next 3Y13.38%
EBIT Next 5YN/A
FCF growth 1Y-26.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.97%
OCF growth 3YN/A
OCF growth 5YN/A